Portal Hypertension Clinical Trial
Official title:
Diagnostic Accuracy of Spleen and Liver Stiffness Measurement by EUS-elastography, to Predict Portal Hypertension in Patients With Cirrhosis.
Patients with cirrhosis have structural and functional alterations of the liver. The progressive deposition of hepatic fibrosis is related to the subsequent development of portal hypertension (PH), and PH is associated with mayor complications including ascites, hepatic encephalopathy and development of gastroesophageal varices with a high risk of bleeding. Variceal bleeding is a medical emergency associated with a 6-week mortality rate of approximately 10-20%. Liver biopsy is the gold standard for the assessment of hepatic fibrosis, whereas the measurement of hepatic vein pressure gradient (HVPG) is the standard to evaluate PH and upper endoscopy (UE) is the method of choice to detect the presence and grade of gastroesophageal varices. The last two also estimates the risk of variceal bleeding. Unfortunately, clinical investigation of PH implies HVPG measurement or endoscopy for esophageal varices (EV) screening and grading. The first one is an invasive technique, mainly restricted to tertiary centers, that requires personal training, increased health care costs and patient discomfort. The UE, even though has demonstrated utility to predict HVPG (HVPG value ≥ 10 mmHg predicts the presence of EV and a value ≥ 12 mmHg is predictive for variceal bleeding), has been criticized of being subjective. Because of this, alternative test including elastographic techniques, have been develop to assess the severity of PH, the presence of EVs and the risk of variceal bleeding. Elastography is a technique used to measure tissue elasticity and stiffness in real time, by the application of slight compression using a transducer to the targeted tissue. The principle is that tissue compression produces deformation (strain) and that the strain is smaller in harder tissue as compared to softer tissue. Consequently, by measuring the tissue strain induced by compression, it is possible to estimate the tissue hardness. Fibroscan® (FS) (Echosens, París, Francia) uses the principle of one-dimension transient elastography (TE) for the assessment of tissue stiffness. It was used initially for liver stiffness measurement (LSM) and proved to be reliable for the diagnosis of liver cirrhosis and avoid liver biopsy in 90% of cases. Also LSM by TE accurately correlates with the severity of PH and the presence of esophageal varices.
More recently, the use of Fibroscan for the spleen stiffness measurement (SSM) has become
particularly attractive to assess. Previous studies have demonstrated that liver cirrhosis
and PH generates some modifications in the spleen such as an increment in size, splenic blood
flow, tissue hyperplasia, and fibrosis that determine an increase in the spleen's density and
tissue stiffness that may be quantified by elastography. The SSM was found to be a valuable
tool for assessing the degree of PH, the presence and severity of EVs and the risk of
variceal bleeding among patients with cirrhosis. Moreover, spleen stiffness as compared with
liver stiffness better represents the dynamic changes occurring in the advanced stages of
cirrhosis and shows higher diagnostic performance in detecting esophageal varices.
Elastography can also be applied by endoscopic ultrasound (EUS-E). The EUS elastography
allowed qualitative and quantitative evaluation. Qualitative elastography evaluates tissue
elasticity by measuring the degree of deformation using a scale in the B-mode image of 1 to
255. This scale is represented by a color map (red- green-blue), wherein hard tissue is shown
in dark blue, tissue with intermediate hardness in green, medium soft tissue in yellow, and
soft tissue in red. There are two options for quantitative elastography and both are based on
the qualitative EUS elastography data, the hue histogram and strain ratio. The hue histogram
represents the overall elasticity within a manually selected area witch is the region of
interest (ROI). The global hardness is being represent by a hue scale from 0 to 250, where 0
represents the hardest and 255 is the softest. The strain ratio (SR) analyzes the
elastographic picture of the target lesion in relation to the surrounding tissues. Two
different areas (A and B) are selected. Area A includes as much of the target lesion as
possible without including the surrounding tissues. Area B is selected within a soft (red)
reference area outside the target lesion, preferably the gut wall. The strain ratio is
calculated as the quotient of B/A.
EUS is also a technique that has proved to be useful to evaluate cirrhotic patients in many
aspects. It allows visualization of a greater part of the portal and portosystemic collateral
circulation. It can be used to detect esophageal and gastric varices witch correlate with the
presence and severity of liver disease and portal hypertension. It can be use to measure
varices size. Large varices (≥ 5 mm) may be risk factors for variceal hemorrhage. It can
visualize paramural collaterals and large vessels such as splenic, portal and azygos veins.
Previous studies have found a significant increase in azygos vein diameter and blood-flow
velocity in patients with varices when compared with control subjects. The evaluation of the
azygos vein using EUS can ad useful information about the porto-systemic collateral
circulation and could help to determine the treatment efficacy. It has been found a decrease
in the azygos vein flow following terlipressin and somatostatin administration, band ligation
or sclerotherapy in patients with portal hypertension. EUS can predict variceal recurrence
after endoscopic therapy. Finally, cirrhosis causes dilation thoracic duct and thickening of
gastric mucosa and submucosa that can be determinate by EUS.
MATERIAL AND METHODS
Study design: This is a prospective, observational, non-randomized and simple blind study,
performed in a Tertiary Academic Center.
Setting: Ecuadorian Institute of Digestive Disease (IECED), Omni Hospital Academic Tertiary
Center. Patients will be recruited from the gastroenterology unit (IECED), from January 2017
to June 2017. The study protocol and consent form has been approved by the Institutional
Review Board and will be conducted according to the declaration of Helsinki. Written informed
consent will be obtained from all participants.
Portal Hypertension determination: The HVPG will be determinate indirectly by upper endoscopy
and clinical examination. A HVPG ≥ 10 mm Hg defines a clinically significant PH (CSPH) and
will be determinate by the presence of EV on UE. On the other hand, a HVPG ≥ 12 mm Hg
indicates a severe PH and will be determinate by the presence variceal bleeding on UE or
ascites and hepatic encephalopathy.
The EUS procedure: The procedure will be performed under general anesthesia, with tracheal
intubation, with the patient in supine position and in an endoscopy suite. All patients will
be initially evaluated by upper endoscopy using a standard gastroscopy in order to avoid any
contraindication and for gastro and esophageal varices assessment. Esophageal varices will be
graded according to the Baveno VI consensus conference as follows: grade I, varices flattened
by insufflation; grade II, varices non-confluent and protruding in the lumen despite
insufflation; grade III, confluent varices not flattened by insufflation. Presence of red
signs, fibrin plugs on the varices, and blood in the upper gastrointestinal tract will be
also recorded. Gastric varices will be classified according to the classification of Sarin
and Kumar. The EUS exam will be performed using a 3.8 mm working channel linear-array
echoendoscopes (EG 3870UTK; Pentax, Hamburg, Germany), attached to an US console (Avius
Hitachi, Tokyo, Japan). Two endoscopists (C.R.M, M.V) with experience in EUS-elastography
will perform the procedures. The exam will start by evaluating the left hepatic lobe (the
closer hepatic segment to the transducer) transgastrically using the conventional B-mode.
Then the elastography software will be activated and the elastographic and B-mode images will
be displayed simultaneously side by side, performing a real time qualitative evaluation of
the hepatic tissue elasticity. The free movement of the endoscope tip, as well as sporadic
motion of the tissues induced by respiratory or heart movements, determines lateral slippage
of the target tissue. In order to avoid that, once the scope is located it will be fixed
using the brakes. Images obtained with the application of strong pressure lead to wrong
measures, so light pressure will be applied. The measurement will be considered adequate when
the gastric mucosa is shown red. Once the transducer is correctly located the quantitative
evaluation will be performed. For the SR calculation, the area A will be manually selected
including as much of hepatic tissue as possible and the area B will be selected on the red
gastric mucosa. For the strain histogram measurement, the ROI selected will have a surface of
60 mm2. Both values will be photographically recorded. The same procedure will be repeated 10
times at different points on the left hepatic lobe and finally the mean SR and SH values will
be calculated. The procedure will continue by measuring the spleen stiffness. The transducer
will be placed as close as possible to the spleen. Patients in whom the distance between the
transducer and the spleen is more than 1.5 cm will be excluded from the analysis, but
included in the intention to treat. The elastography software will be activated and the
previously described sequence will be repeated. Ten measurements will be performed and the
mean SR and SH values will be calculated. Finally the azygos vein (AV) will be scanned in all
patients and evaluated using EUS Doppler. It will be scanned at a distance of 20-30 cm from
the incisors with the EUS probe placed opposite to the posterior wall of the esophagus and to
the right of the vertebral column. After the AV is found it will be followed until its arch.
Measurements of the AV will be performed at a point just caudal to its arch, which drains
into the superior vena cava. The angle of insonation will be less than 60º. The mean velocity
(V mean cm/s) and the AV diameter (D) will be measure and the AV blood flow volume index
(BFVI) will be calculated [BFVI (cm3 /s) = Vmean (cm/s) X D2 (cm2)]. The BFVI has been used
before and it has been found to correlate with the blood-flow volume.
The Fibroscan procedure: In all patients, the liver stiffness measurements (LSM) will be
assesses by transient elastography (TE) using the FibroScan® (FS) (Echosens, Paris, France).
Spleen stiffness (SSM) measurement requires special software not approved by the National
Administration of Food, Drugs and Technology. For the LSM, a previously described technique
will be used. The patients will be in the supine position with arms in maximal abduction. The
TE probe will be applied on the right lobe of the liver, via the intercostal spaces, in the
right axillary midline and perpendicular to the plane of the skin. The results will be
expressed in kilopascals (kPa). At least 10 LSM values will be carried out on each patient.
The FS screen will show 3 parameters that have to be taken into account: the success rate
calculated as the number of valid measurements divided by the number of total measurements,
the median value calculated as average value of the 10 successful measurements and the
interquartile range (IQR) calculated as the deviation of the total of valid measurements with
respect to the median value. According to the manufacturer's recommendations and previous
evidence, an interquartile range (IQR) ≥ 30% of the median value and success rate ≤ 60% will
be considered incorrect and these patients will be excluded from the analysis but included in
the intention to treat. LSM will be performed by two operators (H.P.L, J.O.A.), with more
than 200 procedures performed each, blindly to the EUS-E results.
Statistical analysis: Baseline characteristics as age, gender will be compared between case
and control group. Categorical variables will be assessed using Chi-square o Fisher Test and
continuing variables with Student's t-test or Mann-Whitney Test. The relationships between
the parameters will be characterized using the Spearman correlation coefficients and
Pearson's correlation coefficient. The liver and spleen stiffness elastographic data will be
expressed in kPa. All continuous variables will be expressed in mean ± standard deviation or
median (range) as appropriate. The diagnostic performance of LSM and SSM by EUS elastography
will be assessed using sensitivity (Se), specificity (Sp), positive predictive value (PPV),
negative predictive value (NPV), accuracy, likelihood ratio (LR), Odds ratios (OR) with a 95%
confidence intervals (CI) and receiver-operating characteristic (ROC) curves. Sensitivity
analyses of patients under NSBB treatment prior elastography examination will be perform
separately. Values of P < 0.05 will be considered significant. All the statistical analysis
will be performed using SPSS software suite v.22. (Chicago, IL, USA).
Limitations: Since the examiner will have to choose the best EUS-E images from a dynamic
sequence, a high examiner bias could be certainly favored. Selection of the ROI will be
manually. In case of SH measure, the ROI will have in every case a 60 surface, but for SR
measurement of the area A will have to include as tissue as possible with the possibility of
differences between measurements. There are factors that have been described, especially with
the use of the strain ratio that may influence the results of the elastography calculations.
Examples are the presence of fluid (ascites, cysts, vessels) between the transducer and the
ROI, the degree of compression by the transducer, the ROI diameter, the distance with the
transducer, respiratory and cardiac movements, and the operator's experience. An attempt to
reduce this factors will be apply, however they may not be completely eliminated in all the
cases. The presence of ascites represents a more advanced stage of liver cirrhosis and a high
risk of EV. However, the ascites limits the stiffness measurement by elastography and is
considered and exclusion criteria. Therefore, most of the patients will be classified as
Child-Pugh score A.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05052892 -
A Novel Spleen-dedicated Stiffness Measured by FibroScan to Evaluate Cirrhotic Portal Hypertension (CHESS2105)
|
||
Recruiting |
NCT05251272 -
A Combined Model Based on Spleen Stiffness, Liver Stiffness and Platelets for Assessing Portal Hypertension in Compensated Cirrhosis (CHESS2202)
|
||
Recruiting |
NCT05928624 -
A Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administration of Midodrine Among Decompensated Cirrhosis Patients
|
N/A | |
Recruiting |
NCT04578301 -
Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver Disease
|
||
Not yet recruiting |
NCT05515861 -
Evaluation of EUS in Preventing Rebleeding After Endoscopic Cyanoacrylate Injection for Gastric Varices
|
N/A | |
Recruiting |
NCT02364297 -
TIPS in Fundal Variceal Bleeding (the TFB Study)
|
N/A | |
Recruiting |
NCT01358123 -
Value of Von Willebrand Factor in Portal Hypertension
|
N/A | |
Completed |
NCT00493480 -
Danish Carvedilol Study in Portal Hypertension
|
Phase 3 | |
Recruiting |
NCT06266260 -
Evaluation of the Performance of Direct Portal Pressure Measurement by Endoscopic Ultrasound in a Large Cohort of Patients With Advanced Chronic Liver Disease of Different Etiologies and Newly Diagnosed Clinically Significant Portal Hypertension (EVADIPP)
|
||
Recruiting |
NCT03277651 -
Noninvasive Diagnostic Platform for Liver Fibrosis and Portal Hypertension
|
N/A | |
Active, not recruiting |
NCT03736265 -
Carvedilol for Prevention of Esophageal Varices Progression
|
N/A | |
Completed |
NCT03451149 -
Feasibility And Safety Of Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation Using A Radiofrequency Guidewire
|
N/A | |
Completed |
NCT02994485 -
Evaluation Of The Portal Pressure By Doppler Ultrasound In Cirrhotic Patients Before And After Simvastatin
|
Phase 4 | |
Completed |
NCT01851252 -
MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy
|
Phase 1 | |
Completed |
NCT01923064 -
Injection of Cyanoacrylate+Lipiodol vs Cyanoacrylate+Lauromacrogol in Gastric Varices
|
N/A | |
Completed |
NCT01456286 -
Randomized Controlled Trial to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension
|
Phase 2/Phase 3 | |
Completed |
NCT01551966 -
Esophageal Capsule Endoscopy in Children
|
N/A | |
Completed |
NCT02344719 -
Effect of Taurine on Portal Hemodynamics in Patients With Advanced Liver Cirrhosis
|
Phase 4 | |
Recruiting |
NCT00414713 -
Transfusion Requirements in Gastrointestinal (GI) Bleeding
|
Phase 4 | |
Completed |
NCT00766805 -
Endoscopic Variceal Ligation (EVL)+ Drugs Versus Endoscopic Variceal Ligation (EVL) Alone For Secondary Prophylaxis
|
N/A |